Sugi Predict

Sugi Predict / Compounds / SCHEMBL429472

SCHEMBL429472

SCHEMBL429472

Cc1cccc(NN=Cc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 2/20 0.73
▸ SYK P43405 2/20 0.73
▸ IRAK4 Q9NWZ3 2/20 0.73
▸ FES P07332 1/20 0.73
▸ FER P16591 1/20 0.73
▸ FRK P42685 1/20 0.73
▸ CAMK1D Q8IU85 1/20 0.73
▸ PIKFYVE Q9Y2I7 1/20 0.73
▸ BRSK1 Q8TDC3 1/20 0.56
▸ LMNA P02545 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ PIK3CA P42336 9/20 0.44
▸ PIK3CB P42338 4/20 0.42
▸ PIK3CD O00329 3/20 0.42
▸ PIK3CG P48736 2/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ CDK1 P06493 1/20 0.40
▸ CDK2 P24941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL429471 1.00 TYK2 (0.73) TYK2SYKIRAK4FESFER
SCHEMBL13759009 0.92 TYK2 (0.61) TYK2SYKIRAK4FESFER
SCHEMBL303143 0.90 TYK2 (0.62) TYK2SYKIRAK4FESFER
SCHEMBL303142 0.90 TYK2 (0.62) TYK2SYKIRAK4FESFER
SCHEMBL424652 0.90 TYK2 (0.61) TYK2SYKIRAK4FESFER
SCHEMBL302443 0.90 TYK2 (0.64) TYK2SYKIRAK4FESFER
SCHEMBL302444 0.90 TYK2 (0.64) TYK2SYKIRAK4FESFER
SCHEMBL424653 0.90 TYK2 (0.61) TYK2SYKIRAK4FESFER
SCHEMBL423863 0.89 TYK2 (0.68) TYK2SYKIRAK4FESFER
SCHEMBL423862 0.89 TYK2 (0.68) TYK2SYKIRAK4FESFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935698-B2 Heteroaryl-hydrazone compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2011-05-03 — — US claimed
US-20050282809-A1 Heteroaryl-hydrazone compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-12-22 — — US claimed
US-20210140945-A1 METHODS OF TREATING NEUROLOGICAL DISEASES AND DISORDERS MADRIGAL PHARMACEUTICALS INC (US) 2021-05-13 — — US disclosed
US-20180217130-A1 COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS MADRIGAL PHARMACEUTICALS INC (US) 2018-08-02 — — US disclosed
US-9910031-B2 Compositions and methods for modulating c-Rel-dependent cytokine production MADRIGAL PHARMACEUTICALS, INC. (US) 2018-03-06 — — US disclosed
US-20160003804-A1 COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION ACADIA WOODS PARTNERS, LLC 2016-01-07 — — US disclosed
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 — — US disclosed
US-20120208203-A1 COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION SYNTA PHARMACEUTICALS CORP. (US) 2012-08-16 — — US disclosed
US-20120021434-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-01-26 — — US disclosed
US-7935698-B2 Heteroaryl-hydrazone compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2011-05-03 — — US disclosed
US-20110098267-A1 TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS SYNTA PHARMACEUTICALS CORPORATION (US) 2011-04-28 — — US disclosed
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2009-06-25 — — US disclosed
US-20080227114-A1 COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION SYNTA PHARMACEUTICALS CORP. (US) 2008-09-18 — — US disclosed
WO-2007100759-A2 METHOD FOR TREATING COMMON VARIABLE IMMUNODEFICIENCY SYNTA PHARMACEUTICALS CORP. (US) 2007-09-07 — — WO disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 — — US disclosed
US-20050282232-A1 Compositions and methods for modulating c-Rel-dependent cytokine production SYNTA PHARMACEUTICALS CORP. 2005-12-22 — — US disclosed
US-20050282809-A1 Heteroaryl-hydrazone compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098267-A1 TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS IL17A, IL23R, IL15 TYK2 826/4885SYK 1106/4885IRAK4 381/4885
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS REL, NFATC1, BCL6 TYK2 2464/4885SYK 737/4885IRAK4 660/4885
US-20050282809-A1 Heteroaryl-hydrazone compounds MMP12, IL1RN, CASP12 TYK2 3469/4885SYK 3362/4885IRAK4 639/4885
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS IL17A, IL23R, IL2 TYK2 1275/4885SYK 550/4885IRAK4 120/4885
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders REL, NFATC1, BCL6 TYK2 2464/4885SYK 737/4885IRAK4 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.